Inmune Bio (INMB) Operating Leases (2019 - 2025)
Inmune Bio (INMB) has disclosed Operating Leases for 7 consecutive years, with $411000.0 as the latest value for Q4 2025.
- Quarterly Operating Leases rose 68.44% to $411000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $411000.0 through Dec 2025, up 68.44% year-over-year, with the annual reading at $411000.0 for FY2025, 68.44% up from the prior year.
- Operating Leases hit $411000.0 in Q4 2025 for Inmune Bio, down from $623000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $766000.0 in Q1 2022 to a low of $95000.0 in Q3 2021.
- Historically, Operating Leases has averaged $403950.0 across 5 years, with a median of $404000.0 in 2023.
- Biggest five-year swings in Operating Leases: surged 690.53% in 2022 and later crashed 47.01% in 2024.
- Year by year, Operating Leases stood at $284000.0 in 2021, then surged by 85.21% to $526000.0 in 2022, then fell by 24.52% to $397000.0 in 2023, then crashed by 38.54% to $244000.0 in 2024, then surged by 68.44% to $411000.0 in 2025.
- Business Quant data shows Operating Leases for INMB at $411000.0 in Q4 2025, $623000.0 in Q3 2025, and $451000.0 in Q2 2025.